Xinhua Chen

Key Laboratory Of Public Health Safety, Ministry Of Education
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Corrigendum to "Counterfactual analysis of the 2023 Omicron XBB wave in China" [Infect. Dis. Model. 9 (2024) 195-203].

Corrigendum to "Counterfactual analysis of the 2023 Omicron XBB wave in China" [Infect. Dis. Model. 9 (2024) 195-203].

Journal: Infectious Disease Modelling

Published: August 07, 2024

Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial.

Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial.

Journal: The Journal of infection

Published: August 06, 2024

Counterfactual analysis of the 2023 Omicron XBB wave in China.

Counterfactual analysis of the 2023 Omicron XBB wave in China.

Journal: Infectious Disease Modelling

Published: September 22, 2023

Transplacental transfer efficiency of maternal antibodies against influenza A(H1N1)pdm09 virus and dynamics of naturally acquired antibodies in Chinese children: a longitudinal, paired mother-neonate cohort study.

Transplacental transfer efficiency of maternal antibodies against influenza A(H1N1)pdm09 virus and dynamics of naturally acquired antibodies in Chinese children: a longitudinal, paired mother-neonate cohort study.

Journal: The Lancet. Microbe

Published: December 03, 2022

Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 - China, 2020-2021.

Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 - China, 2020-2021.

Journal: China CDC weekly

Published: November 01, 2022

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.

Journal: Emerging microbes & infections

Published: October 07, 2022

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.

Journal: medRxiv : the preprint server for health sciences

Published: July 28, 2022

The transfer of maternal antibodies and dynamics of maternal and natural infection-induced antibodies against coxsackievirus A16 in Chinese children 0-13 years of age: a longitudinal cohort study.

The transfer of maternal antibodies and dynamics of maternal and natural infection-induced antibodies against coxsackievirus A16 in Chinese children 0-13 years of age: a longitudinal cohort study.

Journal: BMC medicine

Published: May 26, 2022

Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.

Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.

Journal: Emerging microbes & infections

Published: April 05, 2022

Modeling transmission of SARS-CoV-2 Omicron in China.

Modeling transmission of SARS-CoV-2 Omicron in China.

Journal: Nature medicine

Published: March 22, 2022

Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials.

Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials.

Journal: Nature communications

Published: January 24, 2022

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.

Journal: BMC medicine

Published: October 07, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026